GlobeNewswire by notified

Kitron: Q3 2021 - Very strong demand, revenue constrained by component supply

Share

(2021-10-21) Kitron today reported third quarter results showing very strong demand, but also revenue constraints due to the component supply.

Kitron's revenue for the third quarter was NOK 831 million, compared to NOK 1 054 million last year. The decrease is explained by last year’s Corona-related and exceptional volumes within Medical devices, which are now normalized. For the other market sectors combined, demand is very strong, but revenue growth was limited by ongoing component shortages. More than NOK 200 million of demand has been delayed into later quarters.

Profitability expressed as EBIT margin was 6.0 per cent in the third quarter, compared to 8.6 per cent in the same quarter last year. The EBIT margin in the quarter is affected by inefficiencies caused by the component shortage and the fact that the third quarter is seasonally softer. Last year’s EBIT margin was affected by the exceptional Corona-related volumes within the Medical devices sector.

The order backlog ended at NOK 2 568 million, an increase of 38 per cent compared to last year.

Peter Nilsson, Kitron’s CEO, comments:
“Demand continues to be very strong for both 2021 and 2022 with significant growth opportunities in most market sectors. However, the general material supply situation deteriorated rapidly in the third quarter and continues to be a challenge to lead times and deliveries. We currently believe that we are at the worst of these constraints, and we expect the situation to start showing some improvements as we progress into 2022. After last year’s high deliveries of medical devices driven by the Corona pandemic, 2021 has returned to more normal levels with normal seasonality in the third quarter. Given the constraints in the supply chain, I’m satisfied with the results we deliver in the quarter.”

“Currently the raw materials and component supply chain will not support higher output, even though Kitron stands ready to deliver more. Given this year’s increase of inventory and working capital, we now turn our focus to executing demand into deliveries, improving our cash flow, and protecting competitiveness and profitability.”

Mixed sector development
There was revenue growth in the third quarter within the Electrification, Connectivity and Industry sectors, while revenue declined within Defence/Aerospace and, in particular, within Medical devices.

Record order backlog
The order backlog ended at NOK 2 568 million, compared to 1 863 million last year. This is a record and reflects a strong total demand situation but also includes revenue delays due to the component shortage. The order backlog increased within all market sectors. In absolute numbers, the order backlog grew the most within Electrification and Defense/Aerospace, while the percentage growth was particularly strong within Connectivity.

EBIT margin 6.0%
Third quarter operating profit (EBIT) was NOK 50.1 million, compared to 90.5 million last year. EBITDA was NOK 75.7 million, compared to 115.7 million last year.

Profit after tax amounted to NOK 19.5 million, compared to 60.9 million in the same quarter the previous year. This corresponds to earnings per share of NOK 0.11, down from 0.34 last year.

Constraints in supply chain

Operating cash flow was negative NOK 70.2 million, compared to negative NOK 3.2 million in the third quarter last year.

Net working capital was NOK 1 158 million, an increase of 2 per cent compared to the same quarter last year. Net working capital as a percentage of revenue was 31.8 per cent, compared to 25.1 per cent last year. Capital efficiency ratios are heavily affected by the supply shortage, which deteriorated rapidly in the third quarter, with material decommitments and new delivery dates. The material constraints now seem to have levelled out. Management’s focus in the quarter and going forward is on balancing demand with the constraints in supply, executing demand into deliveries and improving cash flow.

Outlook
Total demand is very strong and the order backlog at a record level. However, in the very short term, supply shortages has somewhat limited Kitron's ability to turn demand into revenues, and the outlook for 2021 is adjusted to reflect this.

For 2021, Kitron has previously indicated a revenue outlook of between NOK 3 900 and 4.200 million and an EBIT margin between 6.8 and 7.4 per cent.

Due to the constraints in the supply chain and the resulting delays of revenue, the revenue for 2021 is now expected to be between 3 700 and 3 900 million. EBIT margin is expected to be between 6.8 and 7.1 per cent.

Growth is expected within the Connectivity, Electrification and Industry sectors, whereas there will be a decline within the Medical devices and Defence/Aerospace sectors.

Although the outlook 2021 is adjusted, the backlog and demand situation implies that Kitron remains on the long-term strategic trajectory for revenue and profitability.

The corona situation has so far had limited direct effects but nevertheless brings uncertainty to the outlook together with the constraints in the material supply situation.

Enclosed in PDF are the quarterly report and the presentation. The interim report is presented today at 08:30 a.m. CEST. The presentation will be given in English by CEO Peter Nilsson and CFO Cathrin Nylander, and will be webcast at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20211021_4

For further information, please contact:
Peter Nilsson, President and CEO, tel. +47 94 84 08 50
Cathrin Nylander, CFO, tel: +47 900 43 284
E-mail: investorrelations@kitron.com

Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The company is located in Norway, Sweden, Lithuania, Germany, Poland, China and the United States. Kitron had revenues of about NOK 4.0 billion in 2020 and has about 1 800 employees. www.kitron.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act


Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye